Published in:
Open Access
01-12-2015 | Poster presentation
Impact of retrospective data verification on the results of the academic-led ICON6 trial
Authors:
Andrew Embleton, Elizabeth Clark, Stephen Townsend, Laura Farrelly, Cheryl Jones, Richard Kaplan
Published in:
Trials
|
Special Issue 2/2015
Login to get access
Excerpt
ICON6 (ISRCTN68510403) is a phase III academic-led international double-blind placebo-controlled randomised trial of the addition of cediranib to chemotherapy in recurrent ovarian cancer. The trial established a beneficial gain in progression-free survival (PFS), conducted using the long established risk-based monitoring model as advocated by FDA/EMA as an alternative to the traditional monitoring-intensive industry approach. AstraZeneca are currently considering regulatory submissions using ICON6 as the single pivotal trial. …